Key Points
- Alexander Azoy sold 1,900 shares of Arcus Biosciences on Nov. 26 at an average price of $26.00, trimming his position by 6.49% to 27,363 shares worth about $711,438.
- Arcus reported ($1.27) EPS and $26.0M in quarterly revenue, beating estimates but showing a 45.8% year‑over‑year revenue decline and continued unprofitability (negative net margin and ROE).
- The stock trades near its 1‑year high (~$26), has a $2.81B market cap, and carries a consensus "Moderate Buy" from analysts with a $29.44 target; institutional ownership is high (~92.9%), led by large holders like Vanguard.
Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CAO Alexander Azoy sold 1,900 shares of Arcus Biosciences stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $26.00, for a total value of $49,400.00. Following the completion of the sale, the chief accounting officer directly owned 27,363 shares of the company's stock, valued at approximately $711,438. The trade was a 6.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
Alexander Azoy also recently made the following trade(s):
- On Monday, September 29th, Alexander Azoy sold 2,831 shares of Arcus Biosciences stock. The shares were sold at an average price of $13.00, for a total value of $36,803.00.
- On Friday, September 5th, Alexander Azoy sold 1,579 shares of Arcus Biosciences stock. The shares were sold at an average price of $11.88, for a total value of $18,758.52.
Arcus Biosciences Price Performance
NYSE RCUS opened at $26.02 on Tuesday. Arcus Biosciences, Inc. has a one year low of $6.50 and a one year high of $26.32. The stock has a 50-day moving average of $18.22 and a 200 day moving average of $12.72. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. The company has a market capitalization of $2.81 billion, a price-to-earnings ratio of -7.56 and a beta of 0.74.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The firm had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. During the same quarter last year, the firm posted ($1.00) EPS. The business's quarterly revenue was down 45.8% compared to the same quarter last year. On average, sell-side analysts forecast that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.
Hedge Funds Weigh In On Arcus Biosciences
A number of hedge funds have recently modified their holdings of the company. Victory Capital Management Inc. raised its position in shares of Arcus Biosciences by 36.4% during the 1st quarter. Victory Capital Management Inc. now owns 62,340 shares of the company's stock valued at $489,000 after purchasing an additional 16,622 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Arcus Biosciences in the 1st quarter worth $138,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Arcus Biosciences by 7.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,748 shares of the company's stock valued at $281,000 after acquiring an additional 2,524 shares during the period. US Bancorp DE lifted its position in shares of Arcus Biosciences by 186.9% in the first quarter. US Bancorp DE now owns 19,756 shares of the company's stock valued at $155,000 after acquiring an additional 12,869 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Arcus Biosciences by 24.1% in the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company's stock worth $52,499,000 after acquiring an additional 1,298,584 shares during the period. 92.89% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of equities research analysts have commented on RCUS shares. Wedbush set a $35.00 target price on shares of Arcus Biosciences and gave the stock an "outperform" rating in a research report on Wednesday, October 29th. HC Wainwright lifted their price objective on Arcus Biosciences from $24.00 to $28.00 and gave the stock a "buy" rating in a report on Wednesday, October 29th. The Goldman Sachs Group increased their target price on Arcus Biosciences from $14.00 to $16.00 and gave the company a "neutral" rating in a report on Thursday, October 30th. Truist Financial reissued a "buy" rating and issued a $39.00 target price (up from $32.00) on shares of Arcus Biosciences in a research report on Tuesday, October 7th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Arcus Biosciences in a research note on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Arcus Biosciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.44.
Check Out Our Latest Analysis on Arcus Biosciences
About Arcus Biosciences
(
Get Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
